• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Odonate Therapeutics, Inc.

    7/2/21 4:05:58 PM ET
    $ODT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ODT alert in real time by email
    SC 13G 1 d20248dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.     )*

     

     

    Odonate Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, $0.01 par value per share

    (Title of Class of Securities)

    676079106

    (CUSIP Number)

    June 11, 2021

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications:

    Evan K. Hall, Esq.

    Haynes and Boone, LLP

    2323 Victory Avenue, Suite 700

    Dallas, Texas 75219-7673

    (214) 651-5000

     

     

     


    SCHEDULE 13G

    CUSIP No. 676079106

     

      1    

      Names of Reporting Persons

     

      Ikarian Capital, LLC

      2  

      Check the appropriate box if a member of a Group (see instructions)

      (a)  ☐        (b)  ☒

     

      3  

      Sec Use Only

     

      4  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5     

      Sole Voting Power

     

      0

       6   

      Shared Voting Power

     

      1,986,412

       7   

      Sole Dispositive Power

     

      0

       8   

      Shared Dispositive Power

     

      1,986,412

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,986,412

    10  

      Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

      ☐

    11  

      Percent of class represented by amount in row (9)

     

      5.2% (1)

    12  

      Type of Reporting Person (See Instructions)

     

      IA

     

    (1)

    Based upon 38,507,109 shares of Common Stock, $0.01 par value per share, outstanding as of May 7, 2021, as disclosed in the Issuer’s current report on Form 8-K, filed by the Issuer with the U.S. Securities and Exchange Commission on June 25, 2021.


    SCHEDULE 13G

    CUSIP No. 676079106

     

      1    

      Names of Reporting Persons

     

      Ikarian Healthcare Master Fund, L.P.

      2  

      Check the appropriate box if a member of a Group (see instructions)

      (a)  ☐        (b)  ☒

     

      3  

      Sec Use Only

     

      4  

      Citizenship or Place of Organization

     

      Cayman Islands

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5     

      Sole Voting Power

     

      0

       6   

      Shared Voting Power

     

      1,600,869

       7   

      Sole Dispositive Power

     

      0

       8   

      Shared Dispositive Power

     

      1,600,869

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,600,869

    10  

      Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

      ☐

    11  

      Percent of class represented by amount in row (9)

     

      4.2% (1)

    12  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    Based upon 38,507,109 shares of Common Stock, $0.01 par value per share, outstanding as of May 7, 2021, as disclosed in the Issuer’s current report on Form 8-K, filed by the Issuer with the U.S. Securities and Exchange Commission on June 25, 2021.


    SCHEDULE 13G

    CUSIP No. 676079106

     

      1    

      Names of Reporting Persons

     

      Ikarian Healthcare Fund GP, L.P.

      2  

      Check the appropriate box if a member of a Group (see instructions)

      (a)  ☐        (b)  ☒

     

      3  

      Sec Use Only

     

      4  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5     

      Sole Voting Power

     

      0

       6   

      Shared Voting Power

     

      1,600,869

       7   

      Sole Dispositive Power

     

      0

       8   

      Shared Dispositive Power

     

      1,600,869

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,600,869

    10  

      Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

      ☐

    11  

      Percent of class represented by amount in row (9)

     

      4.2% (1)

    12  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    Based upon 38,507,109 shares of Common Stock, $0.01 par value per share, outstanding as of May 7, 2021, as disclosed in the Issuer’s current report on Form 8-K, filed by the Issuer with the U.S. Securities and Exchange Commission on June 25, 2021.


    SCHEDULE 13G

    CUSIP No. 676079106

     

      1    

      Names of Reporting Persons

     

      Chart Westcott

      2  

      Check the appropriate box if a member of a Group (see instructions)

      (a)  ☐        (b)  ☒

     

      3  

      Sec Use Only

     

      4  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5     

      Sole Voting Power

     

      0

       6   

      Shared Voting Power

     

      1,986,412

       7   

      Sole Dispositive Power

     

      0

       8   

      Shared Dispositive Power

     

      1,986,412

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,986,412

    10  

      Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

      ☐

    11  

      Percent of class represented by amount in row (9)

     

      5.2% (1)

    12  

      Type of Reporting Person (See Instructions)

     

      IN; HC

     

    (1)

    Based upon 38,507,109 shares of Common Stock, $0.01 par value per share, outstanding as of May 7, 2021, as disclosed in the Issuer’s current report on Form 8-K, filed by the Issuer with the U.S. Securities and Exchange Commission on June 25, 2021.


    SCHEDULE 13G

    CUSIP No. 676079106

     

      1    

      Names of Reporting Persons

     

      Neil Shahrestani

      2  

      Check the appropriate box if a member of a Group (see instructions)

      (a)  ☐        (b)  ☒

     

      3  

      Sec Use Only

     

      4  

      Citizenship or Place of Organization

     

      United States of America

    Number of

    Shares

    Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5     

      Sole Voting Power

     

      0

       6   

      Shared Voting Power

     

      1,986,412

       7   

      Sole Dispositive Power

     

      0

       8   

      Shared Dispositive Power

     

      1,986,412

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,986,412

    10  

      Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

      ☐

    11  

      Percent of class represented by amount in row (9)

     

      5.2% (1)

    12  

      Type of Reporting Person (See Instructions)

     

      IN; HC

     

    (1)

    Based upon 38,507,109 shares of Common Stock, $0.01 par value per share, outstanding as of May 7, 2021, as disclosed in the Issuer’s current report on Form 8-K, filed by the Issuer with the U.S. Securities and Exchange Commission on June 25, 2021.


    Item 1.

     

      (a)

    Name of Issuer:

    Odonate Therapeutics, Inc.

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    3 East 28th Street, 10th Floor, New York, New York 10016

     

    Item 2.

     

    (a)

    Name of Person Filing:

    This statement is jointly filed by and on behalf of each of Ikarian Capital, LLC, a Delaware limited liability company (“Ikarian Capital”), Ikarian Healthcare Master Fund, L.P, a Cayman Islands exempted limited partnership (the “Fund”), Ikarian Healthcare Fund GP, L.P., a Delaware limited partnership (“Ikarian GP”), Chart Westcott and Neil Shahrestani (collectively referred herein as the “Reporting Persons”). Ikarian Capital is the investment manager of, and may be deemed to indirectly beneficially own securities owned by, the Fund. Ikarian GP is the general partner of, and may be deemed to indirectly beneficially own securities owned by, the Fund. Ikarian Capital is also the general partner of, and may be deemed to indirectly beneficially own, securities beneficially owned by Ikarian GP. Ikarian Capital is a sub-advisor for certain separate managed accounts (collectively, the “Managed Accounts”) and may be deemed to indirectly beneficially own securities owned by the Managed Accounts. Ikarian Capital is ultimately owned and controlled by Chart Westcott Living Trust, of which Mr. Westcott serves as the sole trustee (the “Trust”), and indirectly by Mr. Shahrestani. Accordingly, each of Mr. Westcott, as sole trustee of the Trust, and Mr. Shahrestani may be deemed to indirectly beneficially own securities beneficially owned by, Ikarian Capital. The Fund and the Managed Accounts are the record and direct beneficial owners of the securities covered by this statement. The Fund disclaims beneficial ownership of the shares held by the Managed Accounts.

    Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

    Each Reporting Person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for the purpose of Section 13(d) or 13(g) of the Act. Each of the Reporting Persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purpose of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the issuer or otherwise with respect to the issuer or any securities of the issuer or (ii) a member of any group with respect to the issuer or any securities of the issuer.

     

    (b)

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of each of the Reporting Persons is c/o Ikarian Capital, LLC, 100 Crescent Court, Suite 1620, Dallas, Texas 75201.

     

    (c)

    Citizenship:

    See Item 4 on the cover page(s) hereto.


    (d)

    Title and Class of Securities:

    Common Stock, $0.01 par value per share

     

    (e)

    CUSIP No.:

    676079106

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)   

    ☐   Broker or dealer registered under Section 15 of the Act;

    (b)   

    ☐   Bank as defined in Section 3(a)(6) of the Act;

    (c)   

    ☐   Insurance company as defined in Section 3(a)(19) of the Act;

    (d)   

    ☐   Investment company registered under Section 8 of the Investment Company Act of 1940;

    (e)   

    ☐   An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

    (f)   

    ☐   An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

    (g)   

    ☐   A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

    (h)   

    ☐   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i)   

    ☐   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

    (j)   

    ☐   A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);

    (k)   

    ☐   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:             

     

    Item 4.

    Ownership

     

    (a)

    Amount Beneficially Owned as of the time of filing: See Item 9 on the cover pages(s) hereto.

     

    (b)

    Percent of Class as of the time of filing: See Item 11 on the cover page(s) hereto.

     

    (c)

    As of the time of filing, number of shares as to which such person has:

     

      (i)

    Sole power to vote or to direct the vote: See Item 5 on the cover pages hereto.

     

      (ii)

    Shared power to vote or to direct the vote: See Item 6 on the cover pages hereto.

     

      (iii)

    Sole power to dispose or to direct the disposition of: See Item 7 on the cover pages hereto.

     

      (iv)

    Shared power to dispose or to direct the disposition of: See Item 8 on the cover pages hereto.


    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following  ☐.

     

    Item 6.

    Ownership of more than Five Percent on Behalf of Another Person.

    The information set forth in Item 2(a) is incorporated by reference herein.

     

    Item 7.

    Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

    Not applicable.

     

    Item 8.

    Identification and classification of members of the group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: July 2, 2021

     

    IKARIAN CAPITAL, LLC
    By:   Chart Westcott Living Trust
    Its:   Manager
    By:  

    /s/ Chart Westcott

      Chart Westcott, Trustee
    IKARIAN HEALTHCARE MASTER FUND, L.P.
    By:   Ikarian Healthcare Fund GP, L.P.
    Its:   General Partner
    By:   Ikarian Capital, LLC
    Its:   General Partner
    By:   Chart Westcott Living Trust
    Its:   Manager
    By:  

    /s/ Chart Westcott

      Chart Westcott, Trustee
    IKARIAN HEALTHCARE FUND GP, L.P.
    By:   Ikarian Capital, LLC
    Its:   General Partner
    By:   Chart Westcott Living Trust
    Its:   Manager
    By:  

    /s/ Chart Westcott

      Chart Westcott, Trustee
    CHART WESTCOTT LIVING TRUST
    By:  

    /s/ Chart Westcott

      Chart Westcott, Trustee
    NEIL SHAHRESTANI

    /s/ Neil Shahrestani


    EXHIBIT INDEX

     

    Exhibit

      

    Description of Exhibit

    99.1    Joint Filing Agreement (filed herewith).
    Get the next $ODT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ODT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ODT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Odonate Announces Expected Delisting of Its Stock

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced that on January 6, 2022 it received written notice from The Nasdaq Stock Market LLC ("Nasdaq") notifying Odonate that Nasdaq believes that Odonate is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. Odonate will not appeal this determination. Therefore, Odonate expects the trading of its common stock on The Nasdaq Stock Market to be suspended at the opening of business on January 18, 2022, and that Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission (the "SEC"), which will remove Odonate's securities from listing and registration on The

      1/7/22 9:00:00 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics Announces Planned Return of Capital to Stockholders through Share Repurchase Plan

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced that it will commence a share repurchase plan for up to 20 million shares in order to return capital to stockholders. This action is in connection with the Company's previously announced decision to discontinue the development of tesetaxel. Repurchases may be made from time to time at the Company's discretion. The plan has no time limit and can be discontinued at any time. There can be no assurance as to the timing or number of shares of any repurchases. As of September 30, 2021, as reported in its recently filed Form 10-Q, the Company had total stockholders' equity of $71.4 million, or $1.85 per share, based on 38.5 million shares ou

      11/17/21 7:45:00 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three and nine months ended September 30, 2021. As of September 30, 2021, Odonate had $95.0 million in cash compared to $157.3 million as of December 31, 2020. Odonate's cash used in operating activities for the three and nine months ended September 30, 2021 was $15.1 million and $63.0 million, respectively. Odonate's net loss for the three and nine months ended September 30, 2021 was $14.0 million and $69.8 million, or $0.37 and $1.85 per share, respectively, compared to $30.5 million and $94.1 million, or $0.93 and $3.00 per share, respectively, for the same periods in 2020. About Odonate Therapeutics, In

      11/10/21 5:15:00 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ODT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Odonate Therapeutics downgraded by Jefferies with a new price target

      Jefferies downgraded Odonate Therapeutics from Buy to Hold and set a new price target of $4.00 from $45.00 previously

      3/22/21 12:46:40 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics downgraded by Cowen

      Cowen downgraded Odonate Therapeutics from Outperform to Market Perform

      3/22/21 11:27:45 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ODT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ODT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ODT
    Financials

    Live finance-specific insights

    See more

    $ODT
    SEC Filings

    See more
    • SEC Form 4: Ecor1 Capital, Llc bought $308,662 worth of shares (185,941 units at $1.66) and sold $9,741,063 worth of shares (5,887,610 units at $1.65)

      4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)

      12/10/21 6:50:07 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Boxer Capital, Llc sold $623,340 worth of shares (400,000 units at $1.56)

      4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)

      11/24/21 6:00:33 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Davis Aaron I. sold $2,499,948 worth of shares (1,200,000 units at $2.08)

      4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)

      11/19/21 7:22:38 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Odonate Therapeutics, Inc. (Amendment)

      SC 13G/A - Odonate Therapeutics, Inc. (0001717452) (Subject)

      12/10/21 5:24:12 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Odonate Therapeutics, Inc. (Amendment)

      SC 13D/A - Odonate Therapeutics, Inc. (0001717452) (Subject)

      11/26/21 5:01:04 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Odonate Therapeutics, Inc. (Amendment)

      SC 13D/A - Odonate Therapeutics, Inc. (0001717452) (Subject)

      11/22/21 11:08:29 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three and nine months ended September 30, 2021. As of September 30, 2021, Odonate had $95.0 million in cash compared to $157.3 million as of December 31, 2020. Odonate's cash used in operating activities for the three and nine months ended September 30, 2021 was $15.1 million and $63.0 million, respectively. Odonate's net loss for the three and nine months ended September 30, 2021 was $14.0 million and $69.8 million, or $0.37 and $1.85 per share, respectively, compared to $30.5 million and $94.1 million, or $0.93 and $3.00 per share, respectively, for the same periods in 2020. About Odonate Therapeutics, In

      11/10/21 5:15:00 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three and six months ended June 30, 2021. In March 2021, Odonate announced the discontinuation of development of tesetaxel and its intent to wind down tesetaxel-related operations. As of June 30, 2021, Odonate has transitioned all patients in tesetaxel studies to appropriate alternative therapies or facilitated continuation of treatment with tesetaxel under compassionate use programs where appropriate. As of June 30, 2021, Odonate had $110.1 million in cash compared to $157.3 million as of December 31, 2020. This decrease in cash resulted primarily from cash used in operating activities for the six months en

      7/27/21 8:30:00 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2021

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three months ended March 31, 2021. Odonate recently announced the discontinuation of development of tesetaxel and its intent to wind down tesetaxel-related operations. Odonate is working with clinical sites to transition patients in ongoing tesetaxel studies to appropriate alternative therapies or facilitate continuation of treatment with tesetaxel under compassionate use programs where appropriate. As of March 31, 2021, Odonate had $133.2 million in cash compared to $157.3 million as of December 31, 2020. This decrease in cash resulted primarily from cash used in operating activities for the three months en

      5/14/21 8:30:00 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 25-NSE filed by Odonate Therapeutics Inc.

      25-NSE - Odonate Therapeutics, Inc. (0001717452) (Subject)

      1/25/22 5:30:50 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics, Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Odonate Therapeutics, Inc. (0001717452) (Filer)

      1/7/22 9:00:35 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Odonate Therapeutics, Inc. (0001717452) (Filer)

      11/18/21 5:00:34 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care